“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...

Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.

Metastasis remains the primary challenge to reducing cancer deaths worldwide, says Memorial Sloan Kettering Cancer Center (MSK) gastrointestinal oncologist Karuna Ganesh, MD, Ph.D.. That's when a ...

In this global network study, researchers examined vitamin B12 levels as a possible biomarker for outcomes in colon cancer.

Takeda Canada Inc. (“Takeda”) is pleased to announce that Ontario Drug Benefit (ODB) include FruzaqlaTM (fruquintinib capsules) in the list of drugs eligible for ...

A toxin in the bacteria that's one of the most common causes of foodborne illness accelerates the spread of colorectal tumors to other parts of the body, a study led by UF Health Cancer Center ...

A study found that a blood test detecting ctDNA after surgery more accurately predicts recurrence and survival in patients with stage 3 colon cancer.

Automatic Classification of Tumor Response From Radiology Reports With Rule-Based Natural Language Processing Integrated Into the Clinical Oncology Workflow Pending validation in larger studies, ctDNA ...

GAINESVILLE, Fla. — A toxin in the bacteria that’s one of the most common causes of foodborne illness accelerates the spread of colorectal tumors to other parts of the body, a study led by UF Health ...

At 26, most people are juggling rent, careers, and group chats, not life-or-death medical decisions. So when a young woman noticed bloating and rectal bleeding, it felt reasonable to blame something ...